Health ❯Healthcare ❯Regulatory Affairs

European Medicines Agency

Drug Approval Process Drug Safety Marketing Authorization Drug Regulation Drug Reviews

GLP-1 Agonists Tied to Higher Risk of Macular Degeneration and Rare Optic Neuropathy

Regulators have updated semaglutide product information to include optic neuropathy as a very rare side effect following new studies on vision risks.

Leqembi Approved by European Regulators for Early-Stage Alzheimer's Treatment

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

EU Regulator Denies Approval for Alzheimer's Drug Lecanemab